期刊
PHARMACEUTICALS
卷 14, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/ph14090926
关键词
atrial fibrillation; atrial electrical remodelling; atrial fibrosis; antifibrillatory drugs; investigational drugs
资金
- National Research Development and Innovation Office [NKFIH K-119992, K-135464, GINOP-2.3.2-15-2016-00006, GINOP-2.3.2-15-2016-00040]
- Ministry of Human Capacities, Hungary [20391-3/2018/FEKUSTRAT, EFOP-3.6.2-16-2017-00006]
- Lorand Eotvos Research Network
- European Union
- European Regional Development Fund [TKP2020-NKA-04]
- National Research, Development and Innovation Fund of Hungary [2020-4.1.1-TKP2020]
Atrial fibrillation is a common cardiac arrhythmia that significantly impacts the health of the elderly population. Intense effort in basic research over the past few decades has advanced understanding of the relationship between atrial remodelling and the development of AF.
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia in the clinical practice. It significantly contributes to the morbidity and mortality of the elderly population. Over the past 25-30 years intense effort in basic research has advanced the understanding of the relationship between the pathophysiology of AF and atrial remodelling. Nowadays it is clear that the various forms of atrial remodelling (electrical, contractile and structural) play crucial role in initiating and maintaining the persistent and permanent types of AF. Unlike in ventricular fibrillation, in AF rapid ectopic firing originating from pulmonary veins and re-entry mechanism may induce and maintain (due to atrial remodelling) this complex cardiac arrhythmia. The present review presents and discusses in detail the latest knowledge on the role of remodelling in AF. Special attention is paid to novel concepts and pharmacological targets presumably relevant to the drug treatment of atrial fibrillation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据